Simultaneous transarterial chemoembolization and radiofrequency ablation for large hepatocellular carcinoma

Table 3 Multivariate analysis using Cox proportional hazard model, n (%)

Characteristics	n	Median OS (mo)	1-yr survival	2-yr survival	3-yr survival	P value
Sex						0.031
Female	4	10.5	2 (50.0)	1 (25.0)	0
Male	42	34.5	31 (73.8)	27 (64.3)	23 (54.5)
Age (yr)						0.264
≤ 60	37	34	26 (70.3)	22 (59.5)	20 (54.1)
> 60	9	35	7 (77.8)	6 (66.7)	4 (44.4)
BCLC staging						0.657
B	10	37.5	8 (80.0)	8 (80.0)	7 (70.0)
C	36	30	25 (69.4)	20 (55.6)	17 (47.2)
Size of tumor (cm)						0.300
8-10	23	34	18 (78.3)	14 (60.9)	12 (51.4)
> 10	23	26	15 (65.2)	14 (60.9)	12 (52.2)
No. of tumors						0.087
Single	35	34	26 (74.3)	23 (65.7)	20 (56.7)
Multiple	11	19	7 (63.6)	5 (54.5)	4 (36.4)
Child–Pugh class						0.640
A	45	34	32 (77.8)	28 (62.2)	24 (53.3)
B	1	19	1 (100)	0	0
Pseudocapsule						0.289
Yes	11	44	10 (90.9)	9 (81.8)	7 (63.6)
No	35	30	23 (65.7)	19 (54.3)	17 (48.2)
Vascular invasion						0.019
Yes	4	8	1 (25.0)	1 (25.0)	0
No	42	34.5	32 (76.2)	27 (64.3)	24 (56.8)
AFP positive1						0.051
Yes	17	14.5	9 (52.9)	6 (35.3)	6 (35.3)
No	29	35	24 (79.3)	22 (75.9)	18 (61.4)

¹AFP ≥ 200 ng/mL. BCLC: Barcelona Clinic Liver Cancer; OS: Overall survival; AFP: α-fetoprotein.